Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

Exclusion Criteria

• •Coagulation disorder other than haemophilia A
• •Present or past FVIII inhibitor (≥0.6 Bethesda units \[BU\]/mL) according to medical history
• •Severe liver or kidney disease (alanine aminotransferase \[ALT\] and/or aspartate aminotransferase \[AST\] levels \>5 times the upper limit of normal; or creatinine \>120 μmol/L)
• •Known hypersensitivity to Nuwiq's active substance or its excipients (sucrose, sodium chloride, calcium chloride dihydrate, arginine hydrochloride, sodium citrate dihydrate, poloxamer 188)
• •Already had surgery in this study
• •Current participation in another interventional clinical trial
• •Treatment with any investigational medicinal product (IMP) within 30 days prior to screening visit